Alpha Tau Medical Ltd.
NASDAQ:DRTSBiotechnology
+$0.04 today
- Market cap
- $1.11B
- Beta
- 1.20
- P/E (TTM)
- -15.2
- EPS (TTM)
- -$0.63
Volume 0.64M
Average 0.69M
DRTS Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Alpha Tau Medical Ltd.NASDAQ: DRTS
Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025
Capital expenditures turns negative
Q4 FY2025 capital expenditures was -$6.08M, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$6.08M. Over 3 fiscal years it compounded at +88.7% a year.
Context
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near -$6.08M or moves back toward the trailing-twelve-month quarterly average of -$1.52M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (6.08M) USD
- Year-over-year change
- -171.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.08M) | -171.4% |
| FY2024 | 2024-12-31 | (2.24M) | +65.0% |
| FY2023 | 2023-12-31 | (6.4M) | -608.1% |
| FY2022 | 2022-12-31 | (904K) | +69.1% |
| FY2021 | 2021-12-31 | (2.93M) | — |
Capital Expenditures vs competitors
How DRTS compares with its peers on the latest reported figures
- DRTS's LTM Dec 2025 capital expenditures of $6.08M is the smallest of the 3 companies compared; the peer median is $12.27M.
- Over three fiscal years its annual growth of +88.7% compares with a peer median of +154.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.95M | -70.1% | +248.2% | 2419.3% | |
| FY2025 | $9.58M | +234.9% | +60.8% | 147.5% | |
| LTM Dec 2025 | $6.08M | — | +88.7% | — | |
| Peer median (excluding DRTS) | $12.27M | +82.4% | +154.5% | 1283.4% | |
Competitors are the stored peer set for DRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.27M) | (33.76M) | (29.16M) | (31.75M) | (42.63M) |
| Depreciation & Amortization | 776K | 979K | 1.07M | 1.1M | 1.23M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 812K | 6.75M | 7.93M | 9.92M | 0 |
| Change in Working Capital | 585K | (307K) | 2.49M | 1.17M | 2.29M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 239K | 220K | 1.14M | 965K | 337K |
| Other Working Capital | 346K | (527K) | 1.35M | 203K | 1.95M |
| Other Non-Cash Items | 13.29M | 2.46M | (293K) | (219K) | 12.42M |
| Operating Cash Flow | (11.81M) | (23.88M) | (17.96M) | (19.78M) | (26.68M) |
| Capital Expenditures | (2.93M) | (904K) | (6.4M) | (2.24M) | (6.08M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (125.08M) | (70.49M) |
| Sales of Investments | 0 | 0 | 0 | 148.19M | 55.98M |
| Other Investing Activities | 22.2M | (89.03M) | 25.08M | (103K) | 0 |
| Investing Cash Flow | 19.27M | (89.94M) | 18.68M | 20.77M | (20.59M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 111K | 3.36M | 49K | 25K | 45.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 93.54M | 5.25M | 0 | 0 |
| Financing Cash Flow | 111K | 96.91M | 5.3M | 25K | 45.77M |
| Effect of Forex Changes | 108K | (258K) | 3.1M | 160K | 501K |
| Net Change in Cash | 7.68M | (17.17M) | 9.12M | 1.17M | (1M) |
| Free Cash Flow | (14.74M) | (24.78M) | (24.36M) | (22.02M) | (32.76M) |
Alpha Tau Medical Ltd.
NASDAQ:DRTS
Intrinsic Alpha fair value
Locked
Current Price
$12.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.